Full Text View
Tabular View
No Study Results Posted
Related Studies
ADVN Biomarker Registry Study
This study is currently recruiting participants.
Verified by National Institute of Allergy and Infectious Diseases (NIAID), May 2009
First Received: October 25, 2007   Last Updated: November 24, 2009   History of Changes
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator: Atopic Dermatitis and Vaccinia Network
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00550316
  Purpose

People with atopic dermatitis (AD), also known as eczema, experience hot, dry, scaly skin with severe itching. In addition, people with AD are prone to skin infections and inflammation. Little is known about the causes of AD. The purpose of this study is to create a registry of people both with and without AD. This registry will be used as a source of data to determine genetic markers for AD and also as a potential participant database for future studies.


Condition
Atopic Dermatitis

Study Type: Observational
Study Design: Case Control, Cross-Sectional
Official Title: ADVN Biomarker Registry Study

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Successful creation of a useful database of clinical and diagnostic information [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Identification and assessment of biomarkers of AD [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Blood samples


Estimated Enrollment: 1000
Study Start Date: May 2006
Estimated Study Completion Date: January 2010
Groups/Cohorts
1
Participants with AD who currently have or have had Eczema Herpeticum (EH)
2
African Americans and Caucasians of non-Hispanic lineage with AD who do not have and have never had EH
3
Participants with AD who currently have or have had Eczema Vaccinatum (EV)
4
Participants with AD who do not have and have never had EV despite receipt of the smallpox vaccination
5
Participants with AD and a currently active case of Molluscum Contagiosum (MC)
6
Participants without AD but who currently have an active case of MC
7
Healthy participants with currently active or history of AD, EH, EV, or MC

Detailed Description:

AD is a chronic, inflammatory skin condition characterized by itching, flaking skin, and a tendency to acquire viral skin infections. The causes and complications of AD are not well understood. The purpose of this study is to establish a registry of people, both with AD and without AD, to help determine genetic markers of AD as well as to contact for participation in future AD studies.

This study will consist of one visit at which the participant's complete medical history will be taken, and blood collection may occur. Participants may be contacted at a later date to participate in future AD studies.

  Eligibility

Ages Eligible for Study:   8 Months to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Participants with and without AD who meet the participation criteria

Criteria

Inclusion Criteria:

  • Meet criteria for one of the AD groups or for healthy volunteer status groups. More information on this criterion can be found in the protocol.
  • Must be non-Hispanic, African American or Caucasian for participation in some groups. See information in Groups above for more information
  • Residing in the United States
  • Parent or legal guardian willing to provide informed consent, if applicable

Exclusion Criteria:

  • Has atopy but lacks stringent AD features (only presumptive diagnosis of AD)
  • History of any systemic illness other than AD
  • Autoimmune or immunodeficiency disease
  • Active systemic malignancy. Participants with uncomplicated non-melanoma skin cancer are not excluded.
  • Any skin disease other than AD that might compromise the stratum corneum barrier (e.g., bullous disease, psoriasis, cutaneous T-cell lymphoma).
  • Investigational research agents within 30 days prior to study entry
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00550316

Contacts
Contact: Judy Lairsmith (303) 270-2413 lairsmithj@NJHealth.org

Locations
United States, California
Univeristy of California at San Diego Recruiting
La Jolla, California, United States
Contact: Monika Gerber     858-657-8390     mogerber@ucsd.edu    
Principal Investigator: Richard Gallo, MD, PhD            
Sub-Investigator: Tissa Hata, MD            
United States, Colorado
National Jewish Health Recruiting
Denver, Colorado, United States
Contact: Judy Lairsmith     303-270-2413     lairsmithj@NJHealth.org    
Principal Investigator: Donald Leung, MD, PhD            
Sub-Investigator: Mark Boguniewicz, MD            
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States
Contact: Candrice R. Heath, MD     773-327-3326     cheath@childrensmemorial.org    
Principal Investigator: Amy Paller, MD            
Children's Memorial Hospital Recruiting
Chicago, Illinois, United States
Contact: Candrice R. Heath, MD     773-327-3326     cheath@childrensmemorial.org    
Principal Investigator: Amy Paller, MD            
United States, Massachusetts
Children's Hospital Boston Recruiting
Boston, Massachusetts, United States
Contact: Lisa Heughan     617-355-6127     lisa.heughan@childrens.harvard.edu    
Principal Investigator: Lynda Schneider, MD            
United States, New York
University of Rochester Medical Center Recruiting
Rochester, New York, United States
Contact: Lorianne Stubbs     585-275-0374     Lorianne_Stubbs@urmc.rochester.edu    
Principal Investigator: Lisa Beck, MD            
United States, Oregon
Oregon Health & Sciences University Recruiting
Portland, Oregon, United States
Contact: Susan Tofte     503-494-6445     toftes@ohsu.edu    
Principal Investigator: Jon Hanifin, MD, PhD            
Sub-Investigator: Eric Simpson, MD            
Sponsors and Collaborators
Atopic Dermatitis and Vaccinia Network
Investigators
Principal Investigator: Lisa Beck, MD University of Rochester
  More Information

Additional Information:
No publications provided

Responsible Party: DAIT/NIAID ( Associate Director, Clinical Research Program )
Study ID Numbers: DAIT ADVN REG 03, Contract #: HHSN266200400033
Study First Received: October 25, 2007
Last Updated: November 24, 2009
ClinicalTrials.gov Identifier: NCT00550316     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Atopic Dermatitis
Eczema
Eczema Herpeticum
Molluscum Contagiousum
Herpes Simplex
Eczema Vaccinatum
Vaccinia

Additional relevant MeSH terms:
Hypersensitivity
Dermatitis, Atopic
Immune System Diseases
Genetic Diseases, Inborn
Skin Diseases
Hypersensitivity, Immediate
Skin Diseases, Eczematous
Skin Diseases, Genetic
Dermatitis

ClinicalTrials.gov processed this record on November 25, 2009